The content on this site is intended for healthcare professionals only
Dr Schilsky presents, at a press conference at ASCO 2015, the Targeted Agent and Profiling Utilization Registry (TAPUR).
It is the first ASCO-led clinical trial, which will offer patients with advanced cancer access to molecularly-targeted cancer drugs and collect "real-world" data on clinical outcomes to help learn the best uses of these drugs outside of indications.
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Uncommon genetic aberrations NTRK, RET, NRG
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
The future of precision oncology
Molecular profiling in prostate cancer: key challenges for clinical implementation
ESMO 2022: Lung roundup
